Latest news for Corem Property (OTC:CPGAF) Stock

Corem Property Group AB is engaged in the acquisition, management, development, and renewal of industrial, storage, logistical and commercial real estates in Sweden and Denmark. Its activities are divided into five geographical regions namely Stockholm, South, West, Smaland, and Malardalen.

COREM PROPERTY GRP B by COREM PROPERTY GROUP

Corem Property Group AB

Baird analyst David Leiker maintains Gentex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNTX#NASDAQ">GNTX</a>) with a Outperform and lowers the price target from $40 to $38.

News

Price Target

Analyst Ratings

GNTX

Baird Maintains Outperform on Gentex, Lowers Price Target to $38

WIIM

BITF

CLSK

COIN

HIVE

MARA

MSTR

RIOT

Shares of crypto-linked stocks are trading higher as Bitcoin rises after Donald Trump advocated for a strategic national crypto stockpile.

$BTC

Bitcoin is trading higher after Donald Trump advocated for a strategic national crypto stockpile and said he would fire SEC Chair Gary Gensler.

Baird analyst Brian Skorney maintains Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) with a Outperform and lowers the price target from $316 to $294.

BIIB

Baird Maintains Outperform on Biogen, Lowers Price Target to $294

Stephens &amp; Co. analyst Russell Gunther maintains SouthState (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SSB#NYSE">SSB</a>) with a Equal-Weight and raises the price target from $88 to $101.

Stephens & Co. Maintains Equal-Weight on SouthState, Raises Price Target to $101

Cannabis

Markets

General

TLRY

Tilray Brands Announced That Aphria RX Has Received A Trading License, Which Will Allow It To Sell And Distribute A Broad Range Of Medical Cannabis Products To Pharmacies, Hospitals, And Medical Wholesalers Throughout Germany

Baird analyst Catherine Schulte maintains Avantor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVTR#NYSE">AVTR</a>) with a Outperform and raises the price target from $26 to $27.

AVTR

Baird Maintains Outperform on Avantor, Raises Price Target to $27

Stephens &amp; Co. analyst Russell Gunther maintains WSFS Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WSFS#NASDAQ">WSFS</a>) with a Overweight and raises the price target from $54 to $62.

WSFS

Stephens & Co. Maintains Overweight on WSFS Financial, Raises Price Target to $62

IOVA

Iovance Biotherapeutics shares are trading lower after Piper Sandler downgraded the stock from Overweight to Neutral and lowered its price target from $19 to $10.

Stephens &amp; Co. analyst Andrew Terrell maintains First Interstate BancSys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIBK#NASDAQ">FIBK</a>) with a Overweight and raises the price target from $32 to $36.

FIBK

Stephens & Co. Maintains Overweight on First Interstate BancSys, Raises Price Target to $36

Baird analyst Joel Beatty maintains argenx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARGX#NASDAQ">ARGX</a>) with a Outperform and raises the price target from $490 to $515.

ARGX

Baird Maintains Outperform on argenx, Raises Price Target to $515

The Dow Jones index closed higher by over 650 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#8217;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/">Benzinga&#8217;s insider transactions</a> platform.
<h3 class="wp-block-heading">ARCA biopharma</h3>
<ul>
<li>The Trade: ARCA biopharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABIO#NASDAQ">ABIO</a>) 10% owner Janus Henderson Biotech Innovation Master Fund Ltd <a href="https://www.benzinga.com/sec/insider-trades/">bought a total of 220,083 shares at</a> an average price of $3.18. To acquire these shares, it cost around $699,165.</li>
<li>What's Happening: On April 25, ARCA biopharma posted a first-quarter loss of 14 cents per share.</li>
<li>What ARCA biopharma Does: ARCA biopharma Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to the development and commercialization of targeted therapies for cardiovascular diseases.</li>
</ul>
<h3 class="wp-block-heading">Anixa Biosciences</h3>
<ul>
<li>The Trade: Anixa Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIX#NASDAQ">ANIX</a>) Director Arnold M Baskies <a href="https://www.benzinga.com/sec/insider-trades/">acquired a total of 5,000 shares at</a> an average price of $3.09. To acquire these shares, it cost around $15,450.</li>
<li>What's Happening: On July 23, Anixa Biosciences announced that its collaborator, Moffit Cancer Center, has received FDA approval for an individual patient Investigational New Drug Application (IND) to allow a second dose of its CAR-T therapy for a patient that may be demonstrating clinical activity to the initial treatment.</li>
<li>What Anixa Biosciences Does: Anixa Biosciences Inc, a cancer-focused biotechnology company, developing vaccines and therapies that are focused on critical unmet needs in oncology.</li>
</ul>
<h3 class="wp-block-heading">Lifeloc Technologies</h3>
<ul>
<li>The Trade: Lifeloc Technologies, Inc. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LCTC#OTC">LCTC</a>) CFO Vern D Kornelsen <a href="https://www.benzinga.com/sec/insider-trades/">acquired a total of 45,620 shares</a> at an average price of $3.80. The insider spent around $173,356 to buy those shares. </li>
<li>What's Happening: On July 26, Lifeloc Technologies named Adam Kashenberg to its Board of Directors.</li>
<li>What Lifeloc Technologies Does: Lifeloc Technologies Inc is a developer, manufacturer, and marketer of portable hand-held and fixed station breathalyzers and related accessories, supplies and education.</li>
</ul>
<h3 class="wp-block-heading">Cyanotech</h3>
<ul>
<li>The Trade: Cyanotech Corporation (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CYAN#OTC">CYAN</a>) Director Michael A / Davis <a href="https://www.benzinga.com/quote/CYAN/analyst-ratings">acquired a total of 10,000 shares </a>at an average price of $0.62. The insider spent around $6,200 to buy those shares.</li>
<li>What's Happening: On June 26, Cyanotech reported net sales of $23,071,000 for fiscal 2024 compared to $23,178,000 in fiscal 2023.</li>
<li>What Cyanotech Does: Cyanotech Corp is engaged in the production of natural products derived from microalgae for the nutritional supplements market.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/07/39984459/top-3-risk-off-stocks-that-are-set-to-fly-in-july">Top 3 Risk Off Stocks That Are Set To Fly In July</a></li>
</ul>

Long Ideas

Penny Stocks

Insider Trades

Pre-Market Outlook

Trading Ideas

ABIO

ANIX

CYAN

LCTC

Anixa Biosciences And 3 Other Stocks Under $5 Insiders Are Buying

Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) had a challenging last week as bulls turned bearish after Elon Musk <a href="https://www.benzinga.com/news/24/07/39953071/tesla-ford-gm-and-other-automakers-trade-lower-in-premarket-after-elon-musk-and-jim-farleys-team-fai">failed to soothe investor worries</a> during the earnings call. However, a top Wall Street analyst has stood by the company&#8217;s stock price target, shifting the focus to the potential value of Tesla&#8217;s non-automotive divisions. 
What Happened: Tesla disclosed <a href="https://www.benzinga.com/news/earnings/24/07/39918390/tesla-q2-earnings-highlights-revenue-beat-eps-miss-robotaxi-update-2024-growth-rate-to-be-notably-l">weaker-than-expected Q2 earnings</a> and the lowest profit margins in half a decade, amid a worldwide EV price war and declining consumer demand. The company also postponed the launch of its highly anticipated robotaxi until October, or possibly later, due to last-minute design modifications.
Despite these hurdles, Morgan Stanley analyst Adam Jonas suggests that investors are excessively focused on the company&#8217;s automotive challenges, while underestimating the potential value of Tesla&#8217;s energy, AI, and robotics divisions. He contends that these sectors could offer greater shareholder value in the long run.
&#8220;While negative developments in the global EV market could impact the stock in the near-term, investors should not overlook Tesla's other plays, including recurring revenue from the Tesla fleet and areas like Energy Storage and Optimus,&#8221; Jonas said in a note.
See Also:&nbsp;<a href="https://www.benzinga.com/money/how-to-buy-tesla-stock" target="_blank" rel="noreferrer noopener">How To Buy Tesla Stock</a>
Jonas held his <a href="https://www.benzinga.com/quote/TSLA/analyst-ratings">$310 price target for Tesla</a>, underscoring that the company&#8217;s AI infrastructure assets are thriving, with shifts in the business mix being overlooked. He also spotlighted the company&#8217;s energy storage sector, which witnessed a record deployment of approximately 9.4 gigawatt hours of energy-storage products in the three months ending in June.
Jonas argues that the value and potential of these divisions now significantly surpass that of Tesla&#8217;s traditional carmaking unit. &#8220;Our thesis views Tesla as both an auto and an energy/AI/robotics company, with the core auto business valuation at $59/share, just ~19% of our $310 target.&#8221; 
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Morgan Stanley&#39;s Adam Jonas: &quot;As <a href="https://twitter.com/Tesla?ref_src=twsrc%5Etfw">@Tesla</a> continues to diversify away from the auto industry and towards the autonomous industrial complex (AIC), we wanted to highlight some interesting information that, while they didn&#39;t grab any headlines, may be consequential over time.&quot; His… <a href="https://t.co/Mlp8TtX7IE">pic.twitter.com/Mlp8TtX7IE</a>
&mdash; Sawyer Merritt (@SawyerMerritt) <a href="https://twitter.com/SawyerMerritt/status/1816841828022251565?ref_src=twsrc%5Etfw">July 26, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
<h4 class="wp-block-heading">Tesla&#8217;s Future Beyond Cars</h4>
CEO Musk has also <a href="https://www.benzinga.com/news/24/07/39923738/tesla-reiterates-new-electric-vehicles-on-track-for-2025-but-ceo-elon-musk-refuses-to-divulge-detail">stressed the profit potential of AI technologies</a> and foresees a surge in capital spending to around $10 billion this year. Despite a 43% slump in earnings per share from last year, Tesla&#8217;s revenues managed to climb 3% to $25.5 billion, buoyed by stronger-than-expected delivery numbers.
Nonetheless, this did not result in higher profit margins, with Tesla&#8217;s gross margin of 14.6% being the lowest in at least five years. Musk has reiterated that full-year deliveries would be &#8220;meaningfully lower&#8221; than last year&#8217;s record tally of around 1.81 million but remains optimistic about the company&#8217;s future beyond carmaking.
<h4 class="wp-block-heading">What Other Analysts Are Saying?</h4>
The Future Fund LLC Managing Partner Gary Black criticized Tesla for its second-quarter earnings, <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39953019/teslas-q2-earnings-lacked-in-analytical-rigor-and-strategic-direction-says-top-anal">citing a lack of analytical rigor</a> and a clear strategy. He highlighted the absence of analytical support for the company's market cap projections and called for a clearer strategy on margin stabilization, marketing, and the rollout of Full Self-Driving features. 
In his latest post, Black, who has significantly reduced his Tesla stake, discussed what would prompt him to increase his position. <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/40004926/tesla-investor-who-significantly-reduced-stake-ready-to-buy-back-in-heres-what-ev-m">He outlined three key points:</a> First, Tesla needs to stabilize and potentially boost auto gross margins by demonstrating a clear path to achieving this goal. Second, evidence of a return to 25%+ volume growth, driven by the launch of sub-$30K EVs, would expand the company's market. Finally, data showing that full self-driving technology can improve from 95%-96% to 99.99% efficacy could justify raising Tesla's price target to $270.
See Also: <a href="https://www.benzinga.com/money/how-to-invest-in-startups" target="_blank" rel="noreferrer noopener">How To Invest In Startups</a>
Stanphyl Capital's Mark Spiegel, a Tesla bear, noted that despite 55% of <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39924771/bubble-fraud-tesla-worth-around-8-40-per-share-stock-valuation-under-scrutiny-as-ev">Tesla's operating income coming </a>from emission credit sales, the overall operating margin was only 6.3%. This is among the worst in the industry, he said. "This is bubble-fraud a car company that should sell at 4x earnings," he added.
However, just like Jonas, Jim Cramer <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39951197/jim-cramer-calls-elon-musk-bankable-and-visionary-as-tesla-shares-fall-over-12-why-">defended the electric vehicle maker</a> and its CEO Elon Musk. While Tesla missed the earnings estimates, Musk told a great story of self-driving technology, energy production, and humanoid robots, Cramer said. If not for the rotation out of big techs, Tesla would have been up in Wednesday's session, he said.
Price Action: Tesla closed Friday's session down 0.20% at $219.80, according to Benzinga Pro data, and has declined 11.52% year-to-date. However, during Monday&#8217;s premarket session, Tesla shares gained 0.80%, according to data from <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/07/39999031/elon-musks-optimism-doesnt-rub-off-on-investors-rivian-ceo-says-r2-not-model-y-copycat-gms-ev-go" target="_blank" rel="noreferrer noopener">Elon Musk's Optimism Doesn't Rub Off On Investors, Rivian CEO Says R2 Not Model Y Copycat, GM's EV Goals Scaled Back Yet Again And More: Biggest EV Stories Of The Week</a></li>
</ul>
Photo courtesy: Shutterstock

Analyst Color

Equities

Tech

TSLA

As Tesla Stock Reels After A Rough Week Following Earnings, Top Analyst Defends Elon Musk's Ambitions For EV Giant Beyond Cars: 'Investors Should Not Overlook Tesla's Other Plays…'

Baird analyst Timothy Wojs maintains Mohawk Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MHK#NYSE">MHK</a>) with a Neutral and raises the price target from $132 to $160.

Baird Maintains Neutral on Mohawk Industries, Raises Price Target to $160

Sabirnetug is the first humanized monoclonal antibody to clinically demonstrate selective target engagement of A&beta;Os in AD patients. Soluble A&beta;Os are a highly toxic form of A&beta; that begin to accumulate before a clinical diagnosis of AD and are an early and persistent trigger of synaptic dysfunction and neurodegeneration. Acumen is developing sabirnetug as a potential next generation antibody treatment for early AD. The company is currently enrolling patients in the ALTITUDE-AD study, a Phase 2 clinical trial designed to evaluate the clinical efficacy and safety of intravenous sabirnetug in patients with early AD.

Biotech

Health Care

ABOS

Acumen Pharmaceuticals Has Dosed The First Subject With A Subcutaneous Formulation Of Sabirnetug (ACU193) In A Phase 1 Pharmacokinetic Comparison Study To Compare Subcutaneous And Intravenous Administrations Of Sabirnetug In Healthy Volunteers

Baird analyst Justin Kleber maintains Floor &amp; Decor Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FND#NYSE">FND</a>) with a Outperform and lowers the price target from $127 to $115.

Baird Maintains Outperform on Floor & Decor Hldgs, Lowers Price Target to $115

ESGR

Enstar To Be Acquired By Sixth Street For $338 Per Share In Cash; Transaction Expected Close In Mid 2025, Subject To Approvals

GSK plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) and Flagship Pioneering (Flagship), the bioplatform innovation company, today announced they have entered a collaboration with the goal of discovering and developing a portfolio of future transformational medicines and vaccines, starting in respiratory and immunology.
This alliance brings together GSK&#39;s disease area expertise and development capability with Flagship&#39;s ecosystem of bioplatform companies, inclusive of its novel modalities and technologies, to make major advances in healthcare.
GSK and Flagship will initially fund up to&nbsp;$150 million&nbsp;upfront to support an exploration phase to identify the most promising concepts for further research and development with Flagship&#39;s bioplatform companies. From these explorations, the collaboration aims to identify a portfolio of up to 10 novel medicines and vaccines which will each be subject to an exclusive option by GSK for further clinical development. Under the terms of the agreement, Flagship and its bioplatform companies will be eligible to receive up to&nbsp;$720 million&nbsp;in upfront, development and commercial milestones from GSK, as well as preclinical funding and tiered royalties, for each acquired programme.

GSK and Flagship Pioneering to Invest $150M in Innovative Health Solutions

&quot;Turning to the export markets, net back pricing for high sulfur Illinois Basin coal has declined to a level that we have decided it is prudent to slow down production for the back half of the year. Therefore, we are adjusting 2024 full-year&nbsp;guidance&nbsp;for our coal operations. At the midpoint, we now expect to sell approximately 34.0 million tons in 2024, or&nbsp;2.6%&nbsp;below the mid-point of our original&nbsp;guidance&nbsp;for the year. Due to the increased summer burn, we now expect more than half of our uncontracted tonnage position will be sold in the domestic market.&quot;

Earnings

Guidance

ARLP

Alliance Resource Partners Updates 2024 Guidance: Now Expects Sales Volumes In Coal Operations Of 33.50M-34.50M Short Tons (prior 34.0M-35.8M Short Tons)

NLSP

NLS Pharmaceutics And Kadimastem Enter Binding Term Sheet For Transaction Under Which Kadimastem will Become A Wholly Owned Subsidiary Of NLS; Kadimastem's Shareholders To Hold 85% Of Issued And Outstanding Shares Of Merged Company

Corem Property

The Only Monthly Membership With a Positive ROI!

-

-

-

-

-

-

-

The Only Monthly Membership With a Positive ROI!

-

-

-

-

-

-

-

Comments

Corem Property

News

Latest news for Corem Property (OTC:CPGAF) Stock